vTv Therapeutics Inc. (VTVT)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
vTv Therapeutics Statistics
Share Statistics
vTv Therapeutics has 2.61M shares outstanding. The number of shares has increased by 7.37% in one year.
Shares Outstanding | 2.61M |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | 7.37% |
Owned by Institutions (%) | n/a |
Shares Floating | 1.48M |
Failed to Deliver (FTD) Shares | 76 |
FTD / Avg. Volume | 0.29% |
Short Selling Information
The latest short interest is 28.85K, so 1.1% of the outstanding shares have been sold short.
Short Interest | 28.85K |
Short % of Shares Out | 1.1% |
Short % of Float | 1.94% |
Short Ratio (days to cover) | 1.5 |
Valuation Ratios
The PE ratio is -1.18 and the forward PE ratio is -42.15.
PE Ratio | -1.18 |
Forward PE | -42.15 |
PS Ratio | 0 |
Forward PS | null |
PB Ratio | -0.97 |
P/FCF Ratio | -1.26 |
PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for vTv Therapeutics Inc..
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 1, with a Debt / Equity ratio of -0.02.
Current Ratio | 1 |
Quick Ratio | 1 |
Debt / Equity | -0.02 |
Total Debt / Capitalization | -2.19 |
Cash Flow / Debt | -36.07 |
Interest Coverage | -1961.69 |
Financial Efficiency
Return on equity (ROE) is 0.82% and return on capital (ROIC) is 141.52%.
Return on Equity (ROE) | 0.82% |
Return on Assets (ROA) | -1.84% |
Return on Capital (ROIC) | 141.52% |
Revenue Per Employee | 0 |
Profits Per Employee | -1.27M |
Employee Count | 16 |
Asset Turnover | 0 |
Inventory Turnover | 0 |
Taxes
Income Tax | 0 |
Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 72.58% in the last 52 weeks. The beta is 0.63, so vTv Therapeutics 's price volatility has been higher than the market average.
Beta | 0.63 |
52-Week Price Change | 72.58% |
50-Day Moving Average | 14.94 |
200-Day Moving Average | 17.78 |
Relative Strength Index (RSI) | 48.48 |
Average Volume (20 Days) | 26.43K |
Income Statement
Revenue | n/a |
Gross Profit | -13.60M |
Operating Income | -25.50M |
Net Income | -20.25M |
EBITDA | -25.41M |
EBIT | n/a |
Earnings Per Share (EPS) | -9.71 |
Balance Sheet
The company has 9.45M in cash and 529.00K in debt, giving a net cash position of 8.92M.
Cash & Cash Equivalents | 9.45M |
Total Debt | 529.00K |
Net Cash | 8.92M |
Retained Earnings | -281.04M |
Total Assets | 43.16M |
Working Capital | 36.53M |
Cash Flow
In the last 12 months, operating cash flow was -19.08M and capital expenditures 0, giving a free cash flow of -19.08M.
Operating Cash Flow | -19.08M |
Capital Expenditures | 0 |
Free Cash Flow | -19.08M |
FCF Per Share | -9.15 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
VTVT does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | -68.87% |
FCF Yield | -51.8% |
Analyst Forecast
The average price target for VTVT is $35, which is 148.2% higher than the current price. The consensus rating is "Buy".
Price Target | $35 |
Price Target Difference | 148.2% |
Analyst Consensus | Buy |
Analyst Count | 1 |
Stock Splits
The last stock split was on Nov 21, 2023. It was a backward split with a ratio of 1:40.
Last Split Date | Nov 21, 2023 |
Split Type | backward |
Split Ratio | 1:40 |
Scores
Altman Z-Score | -9.4 |
Piotroski F-Score | 2 |